Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Dik J. Kwekkeboom(Erasmus MC), Eric P. Krenning(Erasmus MC), Helmut R. Maëcke, Lisa Bodei(European Institute of Oncology), Thomas M. O’Dorisio(University of Iowa), Giovanni Paganelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Lowell Anthony, Larry K. Kvols(Moffitt Cancer Center), Marco Chinol, Stanislas Pauwels, Jan Mueller‐Brand, Roelf Valkema(Active Medicine (United Kingdom))
PubMed
January 1, 2005
Cited by 375
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
|Endocrine Reviews|1991|814